FDA Approves Wegovy (Semaglutide) for Obesity in Teens 12 and Up

FDA approves semaglutide 2.4mg (Wegovy), a once-weekly subcutaneous injection, for treating obesity in adolescents aged 12 years and older.
Medscape Medical News

source https://www.medscape.com/viewarticle/986403?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost